Evidence map›Paper›PMID 38230376›Full record

ArticleFrontiers in pharmacology2023

Brief isoflurane administration as an adjunct treatment to control organophosphate-induced convulsions and neuropathology.

Narayanan Puthillathu, John R Moffett, Alexandru Korotcov, Asamoah Bosomtwi, Ranjini Vengilote, Jishnu K S Krishnan, Erik A Johnson, Peethambaran Arun, Aryan M Namboodiri

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
3.2field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Narayanan PuthillathuDepartment of Anatomy, Physiology, and Genetics, Neuroscience Program and Molecular and Cell Biology Program, Uniformed Services University of the Health Sciences, Bethesda, MD, United States.
John R MoffettDepartment of Anatomy, Physiology, and Genetics, Neuroscience Program and Molecular and Cell Biology Program, Uniformed Services University of the Health Sciences, Bethesda, MD, United States.
Alexandru KorotcovDepartment of Radiology and Radiological Sciences, Uniformed Services University of the Health Sciences, Bethesda, MD, United States.
Asamoah BosomtwiThe Henry M. Jackson Foundation for the Advancement of Military Medicine (HJF), Bethesda, MD, United States.
Ranjini VengiloteDepartment of Anatomy, Physiology, and Genetics, Neuroscience Program and Molecular and Cell Biology Program, Uniformed Services University of the Health Sciences, Bethesda, MD, United States.
Jishnu K S KrishnanDepartment of Anatomy, Physiology, and Genetics, Neuroscience Program and Molecular and Cell Biology Program, Uniformed Services University of the Health Sciences, Bethesda, MD, United States.
Erik A JohnsonDepartment of Neuroscience, United States Army Medical Research Institute of Chemical Defense, Gunpowder, MD, United States.
Peethambaran ArunDepartment of Anatomy, Physiology, and Genetics, Neuroscience Program and Molecular and Cell Biology Program, Uniformed Services University of the Health Sciences, Bethesda, MD, United States.
Aryan M NamboodiriDepartment of Anatomy, Physiology, and Genetics, Neuroscience Program and Molecular and Cell Biology Program, Uniformed Services University of the Health Sciences, Bethesda, MD, United States.
Uniformed Services University of the Health Sciences · USHenry M. Jackson Foundation · USUnited States Army · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Organophosphate-based chemical agents (OP), including nerve agents and certain pesticides such as paraoxon, are potent acetylcholinesterase inhibitors that cause severe convulsions and seizures, leading to permanent central nervous system (CNS) damage if not treated promptly. The current treatment regimen for OP poisoning is intramuscular injection of atropine sulfate with an oxime such as pralidoxime (2-PAM) to mitigate cholinergic over-activation of the somatic musculature and autonomic nervous system. This treatment does not provide protection against CNS cholinergic overactivation and therefore convulsions require additional medication. Benzodiazepines are the currently accepted treatment for OP-induced convulsions, but the convulsions become refractory to these GABA

Indexed as

acetylcholinesterasebrain edemaconvulsant antidote for nerve agentsmagnetic resonance imagingmean diffusivityparaoxon

Identifiers

PMID38230376
PMCPMC10790757
OpenAlexW4389344380

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.